Clinical activity of lenvatinib and pembrolizumab is reported for recurrent nonendometrioid carcinoma, highlighting potential for rare subtypes.
LP therapy demonstrated clinical activity in nonendometrioid carcinoma, including rare subtypes such as carcinosarcoma and mesonephric-like adenocarcinoma. Further accumulation of patients is warranted to validate its efficacy in these uncommon histologic types.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: